Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul;32(7):4922-4930.
doi: 10.1245/s10434-025-17033-1. Epub 2025 Feb 21.

Nonoperative Management of Rectal Cancer: Is "Near-Complete" Response Safe to Surveil?

Catherine N Zivanov  1 , Nathan S Kau  2 , Harika Nalluri-Butz  3 , Oluseye K Oduyale  4 , Ahmed A Eltahir  4 , Jared T Yee  5 , Austin R Dosch  6 , Lindsey Zhang  7 , Hyun Kim  8 , Michael D Iglesia  9 , Michelle L Cowan  5 , Kerri A Ohman  5 , Paul E Wise  5 , Steven R Hunt  5 , Matthew L Silviera  5 , Matthew G Mutch  5 , William C Chapman Jr  5
Affiliations

Nonoperative Management of Rectal Cancer: Is "Near-Complete" Response Safe to Surveil?

Catherine N Zivanov et al. Ann Surg Oncol. 2025 Jul.

Abstract

Background: Nonoperative management of rectal cancer in patients who achieve near-complete response following total neoadjuvant therapy remains controversial and understudied.

Methods: This retrospective cohort study conducted at a tertiary National Cancer Institute-designated cancer center included patients with rectal cancer who initiated active surveillance after achieving near-complete response following induction radiotherapy and consolidation chemotherapy. Near-complete response was determined based on restaging endoluminal evaluation and pelvic magnetic resonance imaging. Time-to-event analyses were used to estimate regrowth-free, proctectomy-free, disease-free, and overall survival.

Results: Of 61 patients who achieved near-complete response and initiated nonoperative management between February 2017 and March 2024, 36 (59.0%) maintained organ preservation with a median follow-up of 27.1 (interquartile range [IQR] 17.4-37.4) months. Twenty-five patients (41.0%) developed local regrowth by a median of 5.7 (IQR 3.2-8.2) months. All regrowths occurred within 17.5 months of initial restaging. Twenty-one patients with regrowth underwent salvage proctectomy, of which 20 (95.2%) achieved R0 resection margins. Following salvage proctectomy, four patients (19.0%) developed local recurrence. Disease-free and overall survival 2 years from restaging were 79.2% (95% confidence interval [CI] 67.0-93.6) and 93.3% (95% CI 86.3-100), respectively. Overall survival was not significantly different between patients with versus without local regrowth (log-rank p = 0.09).

Conclusions: Nonoperative management achieves clinically significant organ preservation rates without compromising oncologic outcomes in patients with near-complete response to total neoadjuvant therapy. Active surveillance allows time for continued evolution of tumor response and may substantially expand organ preservation in a patient population who otherwise would undergo avoidable radical surgery.

Keywords: Near-complete response; Nonoperative management; Organ preservation; Rectal cancer; Watch and wait.

PubMed Disclaimer

Conflict of interest statement

Disclosure: The authors declare no conflicts of interest.

References

    1. Bahadoer RR, Dijkstra EA, van Etten B, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):29–42. doi:10.1016/S1470-2045(20)30555-6 - DOI - PubMed
    1. Cercek A, Roxburgh CSD, Strombom P, et al. Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. JAMA Oncol. 2018;4(6):e180071. doi:10.1001/jamaoncol.2018.0071 - DOI - PMC - PubMed
    1. Kasi A, Abbasi S, Handa S, et al. Total Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020;3(12):e2030097. doi:10.1001/jamanetworkopen.2020.30097 - DOI - PMC - PubMed
    1. Habr-Gama A, Perez RO, Nadalin W, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240(4):711–717; discussion 717–718. doi:10.1097/01.sla.0000141194.27992.32 - DOI - PMC - PubMed
    1. Habr-Gama A, Perez R, Proscurshim I, Gama-Rodrigues J. Complete clinical response after neoadjuvant chemoradiation for distal rectal cancer. Surg Oncol Clin N Am. 2010;19(4):829–845. doi:10.1016/j.soc.2010.08.001 - DOI - PubMed

LinkOut - more resources